6-K filed Jul 21, 2026 at 06:25 ET
Novartis reported Q2 2026 net sales of $14.4B (+3% USD, +1% cc), with core operating income flat at $5.9B (0% cc). Net income declined -19% to $3.3B due to higher taxes and interest expense. Full-year guidance was reaffirmed: low single-digit net sales growth and low single-digit core operating income decline. Strong growth from Kisqali (+43% cc), Kesimpta (+32% cc), and Scemblix (+89% cc) was offset by generic erosion of Entresto (-51% cc). Net debt rose to $39.4B following the $12B Avidity acquisition.